It's not fiction, it's medical reality
Higher diagnostic yield, lower costs

Design and objective

To compare strategies, 60 patients with unexplained syncope were randomized to undergo conventional testing (external loop recorder [ELR], tilt table test [TTT], EP study) or long-term monitoring with a Reveal. Patients who were subsequently undiagnosed were allowed to crossover.

Results

By combining the primary strategy with crossover, the diagnostic yield is 43% with Reveal compared to 20% with conventional testing.
The cost of a primary insertable cardiac monitor strategy is 26% less than that of conventional testing.

 

Early application, more effective treatment

Design and objective

The efficacy of a diagnostic strategy using a Reveal to guide therapy selection was assessed in patients with suspected Neurally Mediated Syncope (more than three severe episodes in two years). For 103 patients Reveal documented the first syncope recurrence. The subsequent treatment was then evaluated.

Results

Reveal documented bradycardia or asystole in 47 patients, who received pacemaker therapy. In 6 others Reveal documented tachyarrhythmia. These patients received catheter ablation, ICD therapy or antiarrhythmic therapy.
For the patient group receiving specific therapy, a 92% relative reduction in syncope burden was realized, compared to the group receiving non-specific therapy. The subset of patients who received a pacemaker, showed a 94% relative reduction in syncope burden.